On January 5, Ildong Pharmaceutical announced that it had held an extraordinary board meeting and appointed Jaeyoon Lee as Co-CEO.

Jaeyoon Lee, Co-CEO of Ildong Pharmaceutical. Ildong Pharmaceutical

Jaeyoon Lee, Co-CEO of Ildong Pharmaceutical. Ildong Pharmaceutical

View original image

Jaeyoon Lee will form a co-CEO structure with Chairman Woongseop Yoon, focusing on driving growth and improving profitability in the company’s core business areas, such as pharmaceuticals and healthcare. He also plans to prioritize generating revenue and securing new growth engines through the commercialization of new drugs, including licensing deals.


Jaeyoon Lee joined Ildong Pharmaceutical in 2022 as Head of the Global Business Division, overseeing global strategy, overseas sales, and business development. Since 2024, as Chief Operating Officer (COO), he has managed not only the global sector but also all major business areas, including sales and marketing, research and development (R&D), and production.


He also concurrently serves as CEO of Ildong Pharmaceutical Group’s R&D affiliates, such as Yunovia and iReeD BMS, playing a key role in new drug R&D and commercialization.



Ildong Pharmaceutical explained that shifting to a co-CEO system is intended to add expertise in research and development (R&D) and global operations to the company’s existing business foundation, thereby establishing a more balanced decision-making structure. The company stated that this move will strengthen accountability and provide greater momentum for executing mid- to long-term strategies aimed at generating profit and securing growth drivers.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing